Core Viewpoint - The stock of Maide Medical (688310) has shown a decline in price and mixed capital flow, indicating potential challenges in market performance and investor sentiment [1][2]. Financial Performance - As of October 22, 2025, Maide Medical's stock closed at 20.88 yuan, down 0.67% with a trading volume of 27,500 hands and a transaction amount of 57.62 million yuan [1]. - The company's main revenue for the first half of 2025 was 141 million yuan, a year-on-year decrease of 14.75%, while the net profit attributable to shareholders was 6.05 million yuan, down 38.81% year-on-year [3]. - The second quarter of 2025 showed a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year, and a net profit of 16.84 million yuan, up 2759.64% year-on-year [3]. Capital Flow Analysis - On October 22, 2025, the net inflow of main funds was 3.99 million yuan, accounting for 6.93% of the total transaction amount, while retail investors saw a net inflow of 2.47 million yuan, representing 4.29% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from speculative funds on several days [2]. Industry Comparison - Maide Medical's total market value is 3.471 billion yuan, significantly lower than the industry average of 7.648 billion yuan, ranking 186 out of 268 in the specialized equipment industry [3]. - The company's price-to-earnings ratio (P/E) stands at 287.07, compared to the industry average of 48.9, indicating a high valuation relative to earnings [3]. - The gross profit margin of Maide Medical is 38.93%, which is above the industry average of 27.76%, but the net profit margin is negative at -1.29%, compared to a positive 0.54% industry average [3].

Group 1 - The core viewpoint of the news is that Maide Medical has seen a stock price increase of 5.16%, reaching 20.77 CNY per share, with a total market capitalization of 3.452 billion CNY [1] - Maide Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main business revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Fund has a significant position in Maide Medical, with 200,000 shares held, accounting for 1.08% of the fund's net value [2] - The Guotai Ju Li Value Flexible Allocation Mixed Fund (005746) has a current scale of 273 million CNY and has achieved a year-to-date return of 5.34% [2] - The fund's performance ranks 6799 out of 8243 in its category for the year and has a cumulative return of 46.8% since its inception [2]

Core Points - Midea Medical's stock price increased by 5.63% this week, closing at 20.07 yuan, with a market capitalization of 3.336 billion yuan [1] - The company reached a weekly high of 21.29 yuan and a low of 18.06 yuan [1] Company Announcements - Midea Medical will hold its first extraordinary general meeting of 2025 on October 30, 2025, to discuss two key proposals [2][3] - The first proposal includes the cancellation of the supervisory board, with the audit committee of the board taking over its responsibilities, and the removal of current supervisors [2][3] - The second proposal involves adjusting the board size from 7 to 8 members, adding one employee representative director, and revising various governance rules [2][3]

证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会会议资料 二〇二五年十月 1 | 2025 年第一次临时股东大会会议须知 3 | | --- | | 2025 年第一次临时股东大会会议议程 6 | | 2025 年第一次临时股东大会会议议案 8 | | 议案一：关于取消监事会、调整董事会人数、修订《公司章程》并办理工商变更登记 | | 的议案 8 | | 议案二：关于修订及制定公司部分治理制度的议案 10 | 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会会议资料 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《迈得医疗工业设备股份有限公司章程》《迈得医疗工 业设备股份有限公司股东大会议事规则》等相关规定，特制定本会议须知： 一、公司负责本次股东大会的议程安排和会务工作，为确认出席大会的股东 或其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身 ...

证券之星消息，10月15日自动化设备板块较上一交易日上涨2.67%，迈得医疗领涨。当日上证指数报收 于3912.21，上涨1.22%。深证成指报收于13118.75，上涨1.73%。自动化设备板块个股涨跌见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300124 汇川技术 | | 1.02 Z | 3.22% | -8119.19万 | -2.55% | -2129.89万 | -0.67% | | 300024 | 机器人 | 3569.61万 | 4.02% | 1348.57万 | 1.52% | -4918.18万 | -5.54% | | 688698 伟创电气 | | 3471.99万 | 7.22% | -2030.96万 | -4.23% | -1441.04万 | -3.00% | | 688306 | 均普智能 | 2851.94万 | 5.28% | -1813.41万 | -3 ...

Core Insights - The medical consumables intelligent equipment industry is experiencing a dual upgrade in scale and quality, driven by the transformation of the manufacturing sector and the localization of medical devices [1][2] - Midea Medical Industrial Equipment Co., Ltd. (stock code: 688310) has over 20 years of experience in the medical consumables intelligent equipment sector, focusing on technological innovation and establishing core competitiveness in areas such as safe infusion and blood purification [1][2] Industry Overview - The Chinese medical device industry is projected to reach a total scale of 1.2 trillion yuan by 2025, with high-value consumables accounting for over 30%, corresponding to a market size exceeding 360 billion yuan [2] - The blood purification product segment is expected to grow significantly, with a market size of approximately 18.7 billion yuan in 2024, reflecting a year-on-year growth of 10% due to the rising number of end-stage renal disease (ESRD) patients [2] - The number of ESRD patients in China reached 4.1259 million in 2023 and is expected to increase to 5.2713 million by 2027, driving demand for automated production equipment for dialysis consumables [2] - The pre-filled syringe market is expanding rapidly, supported by the biopharmaceutical, medical aesthetics, and vaccine sectors, with a shift from Western markets to domestic production [2] - The "14th Five-Year" medical equipment industry development plan emphasizes support for the localization of high-end medical equipment, aiming for over 50% of county-level hospitals to procure domestic CTs by 2025 [2] Company Performance - Midea Medical focuses on intelligent equipment for medical consumables, including safe infusion, blood purification, and drug-device combination solutions, offering a full chain of solutions from single machines to connected systems [3] - The company has made significant advancements in blood purification equipment, breaking foreign monopolies with its domestically produced medical dialysis equipment [3] - Despite market fluctuations and longer production cycles, the company demonstrated resilience with R&D investment reaching 17.9772 million yuan, accounting for 12.75% of revenue, an increase of 0.48 percentage points year-on-year [4] - The net cash flow from operating activities reached 110 million yuan, a substantial year-on-year increase of 243.90%, indicating improved cash flow [4] Competitive Advantages - The company possesses strong core competencies across technology, R&D, customer relations, and market presence, with 18 key technologies, including advanced solvent bonding technology that reduces glue usage by 20% [5] - Midea Medical has established long-term partnerships with leading domestic medical consumables companies and has entered the supply chains of international clients [5] - The company has maintained the highest market share in its industry for three consecutive years from 2022 to 2024, showcasing its significant first-mover advantage [5] New Business Development - Midea Medical is expanding its growth avenues through its subsidiary, Midea Shun, which is focusing on the contact lens CDMO business, addressing domestic outsourcing gaps [6] - The company is also making strides in international markets by building overseas R&D and sales networks, aiming to extend its cost and technological advantages globally [6]

Market Overview - The Shanghai Composite Index is at 3878.54 points, below the five-day moving average, with a change of 0.34% [1] - The total trading volume of A-shares is 946.108 billion yuan [1] Stocks Performance - A total of 854 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Xiangrikui (向日葵) with a deviation rate of 12.17% and a daily increase of 19.97% [1] - Heshun Electric (和顺电气) with a deviation rate of 10.53% and a daily increase of 13.57% [1] - Guangzi International (广咨国际) with a deviation rate of 8.38% and a daily increase of 12.14% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Fute Technology (富特科技) with a deviation rate of 7.46% and a daily increase of 9.54% [1] - Xiangjiang Holdings (香江控股) with a deviation rate of 7.31% and a daily increase of 10.10% [1] - Anglikang (昂利康) with a deviation rate of 7.07% and a daily increase of 10.01% [1] Summary of Key Stocks - The following stocks have shown significant trading activity: - Jiuchisoft (久其软件) with a daily increase of 10.03% [1] - Yuanda Intelligent (远大智能) with a daily increase of 9.97% [1] - Anner (安奈儿) with a daily increase of 7.30% [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-038 迈得医疗工业设备股份有限公司 关于取消监事会、调整董事会人数、修订《公司章程》并办 理工商变更登记及修订和制定部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"或"迈得医疗"）于2025年 10月9日召开第五届董事会第四次会议，审议通过了《关于取消监事会、调整董 事会人数、修订〈公司章程〉并办理工商变更登记的议案》《关于修订及制定公 司部分治理制度的议案》，同日召开第五届监事会第四次会议审议通过了《关于 取消监事会、调整董事会人数、修订〈公司章程〉并办理工商变更登记的议案》， 相关议案尚需提交公司股东大会审议。具体情况如下： 根据《中华人民共和国公司法》（以下简称"《公司法》"）《关于新〈公司 法〉配套制度规则实施相关过渡期安排》《上市公司章程指引》等有关法律法规 和规范性文件的规定，并结合公司实际情况，公司将不再设置监事会与监事，并 对董事会人数进行调整，同时对《公司章程》进行修订并办理 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-039 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 30 日 至2025 年 10 月 30 日 迈得医疗工业设备股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 10 月 30 日 13 点 30 分 召开地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设备股份有限公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 本次股东大会审议议案及投票股东类型 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年10月30日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 ...

经与会监事审议表决，通过了如下议案： 证券代码：688310 证券简称：迈得医疗 公告编号：2025-037 迈得医疗工业设备股份有限公司 第五届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第五届监事会第四次会 议（以下简称"本次会议"）于 2025 年 10 月 9 日以现场表决方式在公司会议室召 开。本次会议的通知已于 2025 年 9 月 30 日以电子邮件方式送达全体监事。本次 会议由监事会主席吴江平先生主持，应出席会议监事 3 人，实际出席会议监事 3 人。本次会议的召开符合《中华人民共和国公司法》等法律、行政法规以及《迈 得医疗工业设备股份有限公司章程》的相关规定。 二、监事会会议审议情况 (一)审议通过了《关于取消监事会、调整董事会人数、修订〈公司章程〉并 办理工商变更登记的议案》 根据相关规定，公司将不再设置监事会与监事，由董事会审计委员会行使《公 司法》规定的监事会职权。自公司股东大会审议通过取消监事会事 ...